Sanz Rubiales A, García Alvarez G, Centeno Cortés C, Martín Ortega Y, Del Valle Rivero A L, Nieto Sanz J
Servicio de Oncología, Hospital Universitario, Valladolid.
An Med Interna. 1998 Feb;15(2):100-4.
We review the randomized trials published so far comparing the use of colony-stimulating factors (both G-CSF and GM-CSF) as adjunctive care in chemotherapy-induced neutropenic fever. With this treatment a slight one day reduction in duration of neutropenia under 500 neutrophils per mm3 is observed; this effect seems to be more important in prolonged neutropenias. The number of days with fever remain unchanged. No clear benefit expressed as clinical and quality of life improvement or economical saving is proved. According to these results, and as previous recommendation about the use of colony-stimulating factors pointed out, the indications for administration of such cytokines in neutropenic fever are restrictive and its use could be acceptable only in patients with poor prognostic factors.
我们回顾了迄今为止发表的关于在化疗引起的中性粒细胞减少性发热中使用集落刺激因子（包括粒细胞集落刺激因子和粒细胞巨噬细胞集落刺激因子）作为辅助治疗的随机试验。采用这种治疗方法，观察到中性粒细胞计数低于每立方毫米500个中性粒细胞的中性粒细胞减少持续时间略有缩短一天；这种效应在持续性中性粒细胞减少中似乎更为显著。发热天数保持不变。未证实有以临床和生活质量改善或节省费用表示的明显益处。根据这些结果，正如之前关于使用集落刺激因子的建议所指出的，在中性粒细胞减少性发热中使用此类细胞因子的指征是严格的，仅在预后不良因素的患者中使用才可能是可接受的。
